|
KMID : 0388120120210040197
|
|
Journal of Korean Society for the Study of Obesity
2012 Volume.21 No. 4 p.197 ~ p.202
|
|
|
Drug Therapy for Obesity
|
|
Kim Kyung-Soo
Park Seok-Won
|
|
|
Abstract
|
|
|
|
Obesity is associated with a substantial increase in metabolic disorders and various cancers. As weight loss achieved with lifestyle intervention is modest, there is a need for drug treatment. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. Among these drugs, orlistat is the only approved drug for long-term weight management. The U.S. Food and Drug Administration approved lorcaserin for treatment of obesity in June 2012. Qsymia is a combination of phentermine and topiramate that was approved by USFDA in July 2012. There are currently a large number of drugs for the treatment of obesity undergoing research and development. Drug therapy may play an important role in the treatment of obesity.
|
|
|
KEYWORD
|
|
|
Obesity, Drug therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|